by Rod Raynovich | Jul 18, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Todays’ Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate support of 100.The healthcare sector overall was down 0.88%...
by Rod Raynovich | Jul 16, 2011 | BIOgraph, Life Science ETF's and Mutual Funds
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for investors and recent breakthroughs with new drugs and devices have...
by Rod Raynovich | Jul 15, 2011 | BIOgraph, Macro
Large cap drug and biotech stocks sold off as buyers favor technology. Within the NASDAQ-100 up 1% led by GOOG, BIDU and SIRI. Alexion (ALXN $52.19) bucked the weakness in biotech up 1.74% but GILD, ILMN and AMGN down. Some major rotation going on today out of...
by Rod Raynovich | Jul 14, 2011 | 2023-24 Life Science Portfolios, BIOgraph, Reading List
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom about European debt, US debt ceiling and potential default. JPMorgan...
by Rod Raynovich | Jul 12, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by...
by Rod Raynovich | Jul 8, 2011 | BIOgraph, Reading List
A front page article in the New York Times today by Gina Kolata, “How Bright Promise in Cancer Testing Fell Apart”, chronicles a patient case study at Duke University about gene based tests for lung cancer. Additional commentary at other research...
by Rod Raynovich | Jul 6, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular Systems (CSII) up 32.5%,Exact Scientific (EXAS) up 42%, and GenProbe...
by Rod Raynovich | Jul 5, 2011 | 2023-24 Life Science Portfolios
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in April 2010 at a price of $20.
by Rod Raynovich | Jul 4, 2011 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF’s and Life Science mutual funds. Our two recommended biotech ETF’s for balancing and overweighting were FBT up...